From AFR Live:
Acadia expands Neuren licensing deal
The sharemarket’s hottest junior biotech Neuren has signed an expanded licensing deal with its US distribution partner Acadia.
Neuren owns the rights to the DAYBUE drug to treat Rett syndrome children.
“This expanded worldwide agreement solidifies Acadia’s position as the global leader in addressing the unmet needs of people with Rett syndrome,” said Steve Davis, Acadia’s president and chief executive officer. “We have successfully delivered DAYBUE, the first FDA-approved therapy that treats the core symptoms of Rett syndrome, and are deeply committed to broadening access to this important therapy for patients worldwide.”
Neuren shares are up 324 per cent in five years on a market value of $1.48 billion.
Acadia shares are up 20 per cent in after hours markets in New York.
(20min delay)